Point-of-Care Troponin Product Meets Guidelines for Heart Attack Detection

A point-of-care troponin product is capable of meeting all of the guidelines stipulated by the world's leading cardiac organizations for detection.

Trinity Biotech (Wicklow, Ireland) has announced European approval of a guideline compliant, point-of-care, high sensitivity Troponin I product. That is, the troponin I product has received the CE marking for its Meritas, high sensitivity Troponin I (hsTnI) product. Troponin is the leading marker used in the detection of heart attacks or myocardial infarctions (MI).

The worldwide segment for Cardiac Troponin testing is estimated to be USD 1.2 billion, growing at a rate of 12% per annum. Of this market, approximately USD 350 million represents point-of-care testing carried out in the Emergency Room (ER) with the remainder being laboratory based testing.

This test delivers sensitivity and precision at the point-of-care, which allows doctors to evaluate whether or not patients are having a heart attack within a short time of admission.

The future plans of Trinity Biotech will include an immediate launch of its Troponin product for sale in Europe and as well as commencement of US trials with the aim of receiving the US Food and Drug Administration (Silver Spring, MD, USA) approval.

Related Links:
Trinity Biotech
US Food and Drug Administration